First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers

Tang, Fei, Kunder, Rebecca, Chu, Tom · Clinical and Translational Science · 2023